Broncholab
Overview
Broncholab, developed by Fluidda, is an AI-powered diagnostic platform that utilizes Functional Respiratory Imaging (FRI) technology to provide detailed, regional lung function insights. It analyzes high-resolution CT scan data to deliver quantitative parameters for pulmonary tissue, assisting physicians in the diagnosis, documentation, and monitoring of various respiratory conditions.
The platform converts CT scan images into three-dimensional reconstructions of anatomical structures, such as airways and lung volumes, and employs accurate computer simulations, including Computational Fluid Dynamics (CFD), to add a unique level of functionality to the scan output. This technology provides reproducible CT values for pulmonary tissue, offering quantitative support for diagnosis and follow-up examinations.
Broncholab’s capabilities extend to 3D segmentation and isolation of sub-compartments, volumetric analysis, density evaluations, low-density cluster analysis, fissure evaluation, and comprehensive reporting tools, all integrated into a dedicated workflow. It aims to provide more accurate and clinically relevant information than conventional lung function tests, enabling early and correct diagnosis and optimizing treatments for individual patients.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Functional Respiratory Imaging (FRI)
- Quantitative HRCT analysis
- Regional lung function visualization
- Disease progression monitoring
- Therapy optimization support
- 3D segmentation and isolation of sub-compartments
- Volumetric analysis
- Density evaluations
- Low density cluster analysis
- Fissure evaluation
- Reporting tools
- Computational Fluid Dynamics (CFD)
- AI/Machine Learning algorithms
Use Cases
- Diagnosing respiratory diseases
- Monitoring respiratory diseases
- Optimizing treatment for individual patients
- Early and correct diagnosis of lung conditions
- Supporting clinical trials for new respiratory drugs
- Assessing patient's lung function and disease progression
- Detecting changes in lung structure (e.g., pulmonary vascular remodeling)
- Personalized medicine for respiratory care
What Physicians Need to Know
Broncholab offers quantitative, regional lung function insights that go beyond conventional spirometry, enabling more accurate and early diagnosis, personalized treatment optimization, and effective monitoring of disease progression and therapy effects. It provides valuable biomarkers such as nodule and airway volume, trapped air pockets, and ventilation maps, and can predict drug particle deposition. This tool is particularly beneficial for patients with complex respiratory conditions or when standard tests may underestimate disease severity, aiding in timely adjustments to therapy and potentially reducing the need for invasive procedures.
Broncholab operates as a Software as a Medical Device (SaMD) accessible via a secure online portal for uploading CT scan data. It requires DICOM 3.0 compliant CT images as input and integrates by saving generated reports directly to the hospital's PACS.
Details
| Category | Radiology & Imaging AI |
| Pricing | Contact for pricing — Not publicly available; contact vendor for details. |
| Deployment | SaaS (online platform/web portal) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The FDA provided market clearance to Fluidda for its Broncholab platform (K191550) in March 2020. Broncholab is a Software as Medical Device (SaMD) that provides quantitative CT values to support physicians in the diagnosis and documentation of pulmonary tissue images from CT scans. |
| Integrations | |
| EHR | Not specified |
| Specialties | Pulmonology, Radiology |
What the Web Says
Broncholab, developed by Fluidda, is an online platform that utilizes Functional Respiratory Imaging (FRI) to provide physicians with detailed quantitative analysis of CT scan data for diagnosing and monitoring respiratory diseases. It received FDA clearance in March 2020 and aims to offer more accurate and personalized insights into lung function compared to conventional tests like spirometry.nnThe platform is designed to assist in early and correct diagnosis, optimize treatment strategies, and has been used in clinical trials for drug development.
Overall: PositiveStrengths
- Provides unique, detailed regional lung function insights through Functional Respiratory Imaging (FRI).
- Offers enhanced sensitivity for diagnosing and monitoring respiratory diseases.
- Can optimize therapy and predict drug deposition in the lungs.
- Yields more accurate regional information than conventional lung function tests.
- Supports physicians in diagnosis and documentation of pulmonary tissue images.
- Potential for cost savings by quickly reviewing expensive treatments and avoiding unnecessary adverse effects.
Limitations
- Limited to SaaS deployment, which may not suit all enterprise IT infrastructures.
- Focuses on niche diagnostic capabilities for pulmonology rather than broad workflow needs.
- No specific user ratings or reviews found on G2 or Capterra for Broncholab itself.
- Initial focus on patients whose treatment options have been exhausted, not for all patients immediately.
Based on reviews from: Broncholab, QuickRad vs Broncholab - Physician AI Tools, FDA clears Fluidda's digital lung imaging platform for respiratory disease monitoring, FDA clears Fluidda respiratory imaging platform - AuntMinnie, FLUIDDA'S Magazine on Functional - OINDP News, Functional Respiratory Imaging - An innovation at just the right time - Pharma Focus Asia, FDA Clears Fluidda's Broncholab Platform for Use in Clinical Practice - PR Newswire
Last updated: 2026-07-17
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Broncholab
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Broncholab.
Innovative solutions for detecting and treating lung diseases:Interview with FLUIDDA's Jan De Backer
Frequently Asked Questions
Compare Broncholab
VS
VS
VS
